Recombinant equine growth hormone administration: effects on synovial fluid biomarkers and cartilage metabolism in horses.
Authors: Dart A J, Little C B, Hughes C E, Chu O, Dowling B A, Hodgson D R, Rose R J, Johnson K A
Journal: Equine veterinary journal
Summary
# Editorial Summary: Recombinant Equine Growth Hormone and Joint Metabolism Recombinant equine growth hormone (reGH) has potential value for improving body condition and wound healing, but its effects on articular cartilage metabolism—mediated through insulin-like growth factor-1 (IGF-1)—remained unclear. Dart and colleagues administered 20 micrograms per kilogram of reGH intramuscularly daily for 8 weeks to six horses, with three control animals receiving saline, measuring serum and synovial fluid samples across 16 weeks and harvesting cartilage for biochemical analysis. Whilst IGF-1 concentrations in both serum and synovial fluid increased significantly at 6 and 8 weeks post-treatment, the most notable finding was a reduction in synovial fluid glycosaminoglycan concentrations during this period—suggesting reGH modulates proteoglycan turnover without triggering degenerative changes. Crucially, cartilage from treated horses showed no evidence of the catabolic markers associated with early osteoarthritis (altered aggrecan epitopes, increased link protein degradation, or abnormal epitope patterns), indicating the metabolic shift was not pathological. These results suggest intramuscular reGH administration could offer a practical delivery route for targeting IGF-1 to joints during cartilage-repair protocols, though practitioners should note this work established safety rather than efficacy for cartilage healing.
Read the full abstract on PubMed
Practical Takeaways
- •reGH appears safe for joint health with no osteoarthritis markers detected over 16 weeks, offering potential as a therapeutic option for cartilage repair in sport horses
- •The significant reduction in synovial fluid glycosaminoglycans suggests reGH may actively modulate cartilage metabolism rather than cause passive effects
- •Intramuscular delivery proved effective for achieving therapeutic IGF-1 levels in synovial fluid, providing a practical administration route for joint-targeting therapies
Key Findings
- •Recombinant equine growth hormone (20 µg/kg daily for 8 weeks) significantly elevated IGF-1 in serum and synovial fluid at 6 and 8 weeks (P < 0.05)
- •Glycosaminoglycan concentrations in synovial fluid were significantly reduced in reGH-treated horses at 6 and 8 weeks, suggesting modulation of proteoglycan metabolism
- •No markers indicative of osteoarthritis development were detected in cartilage, including 3B3(-) epitope, aggrecan metabolites, or link protein catabolites
- •Intramuscular reGH administration may be an efficient delivery method for IGF-1 to joints for cartilage resurfacing